The ATTD 2026 has drawn to a close. Welcome to the EASD e-Learning Newsflash with our final report on the latest developments in advanced technologies and treatments for diabetes. We begin with Dr Amit Gupta who presented global insights on the future of diabetes education. If we look from the global perspective, the need for education, I believe, is now very high. In high-income countries there are structured learning pathways and structured CMEs while in low-income countries, the education is mostly based on conferences and workshops. The gaps which I could identify is that as we see that some of the practitioners, they may be very busy. At the same time, the content may not align exactly with their requirements, and the mode of practise is also different. For example, in US or Europe, you may think of talking about precision medicine, advanced technologies, but in some of the low-income countries, middle-income countries, the priority areas would be how to strengthen the primary care ecosystem. Another challenge is that now is the time when we think of content which can be integrated into the clinical workflow. We need to think of bite-sized content, the micro learning contents, some online journal clubs which can be delivered. The applications of CGM are evolving. Lutz Heinemann co-chaired a session on new areas of CGM use beyond the traditional type 1 diabetes management. Let me start with a little bit of a fun thing. I also see a use for CGM in pets, in other words in cats and dogs and so on. So a little bit more serious. Many athletes are interested in continuous glucose monitoring to optimise their performance. So then going next step is then in non-diabetic subjects, some of them would like to see what is their response to a given food item and so on in order to optimise their postprandial glycaemic control, the beer that I’m drinking, what it does to my glycaemia. What happens if I have two pieces of cake instead of one? And in this respect, it’s also for all of us somewhat of interest to see how does glycaemia react to different lifestyle interventions, exercise, sleep, sick days, menstrual cycle and so on. To wrap up this EASD e-Learning Newsflash series, we met up with this year’s ATTD Breakthrough Outcomes Award recipient, EASD Past-President Chantal Mathieu. Professor Mathieu, congratulations. What do you think are the greatest achievements that have improved diabetes care? We have seen really a new face of type 1 diabetes where we have better insulins to treat people living with type 1 diabetes, better basal insulins, better mealtime insulins, and then this technology coming in. First of all, the CGMs, and then the connection with the pumps, and the smart algorithms giving us hybrid closed loop systems. And now at this conference presented also fully closed loop systems, meaning that people will not have to bolus anymore for meals. So it’s a completely new face of those living with type 1 diabetes, but also the hope that we have now that we will be able to prevent the disease and eventually also cure the disease. And this is still your work. So moving on to your presentation that you gave today about C-peptide levels and functional beta cell mass. For 100 years, we’ve now been doing metabolic therapy of people with type 1 diabetes. Namely, we wait until the beta cell is completely destroyed and then we start with replacing all the functions of the beta cell with insulin. But we’re moving now into uncharted territory, namely with disease-modifying therapies. So we will need other endpoints, we will need other biomarkers telling us that the therapies are actually working on affecting the course of the disease. And I believe that C-peptide is one of these measures. We have arguments to say that, indeed, C-peptide is a reflection of functional beta cell mass and it gives you an indication of also future complications. So it is really a plea now to the regulators to allow us to use C-peptide as an endpoint in clinical trials of disease-modifying therapies without having to do very long trials, for instance, in people with stage 3 T1D to pick up the subtle metabolic effects, because it delays progression of clinical development of these disease-modifying therapies. And so we need to move this field forward. It’s uncharted terrain, but I do believe that the evidence in the literature is strong enough to really go back to the regulators and say it’s time now, and we just published in Diabetes Care a call-to-action paper on that specific topic of C-peptide as an endpoint for regulatory trials. Thank you all for watching and following the latest in diabetes research with EASD e-Learning. Until next time.